Atlas Trials

A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

Clinical trial NCT06632990 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06632990
Sponsor
Allyx Therapeutics
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Drug Drug Interaction (DDI)
Start date
2024-11-04
Primary completion
2025-04-03
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.